Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers

NCT04328844 is registered in ClinicalTrials.gov with iOnctura as lead sponsor.

NCT NCT04328844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04328844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers
Lead sponsor
iOnctura
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 25, 2020
Completion date
March 31, 2028
Enrollment
210 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, non-hodgkin lymphoma, adult, nsclc, solid tumor, adult, uveal melanoma